文献速递肝病

自发性细菌性腹膜炎的临床结局与诊疗:一项全国性队列研究

Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study.
PubMed 文献 · Hepatology · 2025-01-29

该全国性队列纳入4330例新诊断的自发性细菌性腹膜炎(SBP)患者,分析腹水特征、院内及12个月死亡率、急性肾损伤(AKI)和SBP复发,并评估各项及集束化质量指标与结局的关联。结果显示院内死亡率为15.5%、12个月死亡率为56.6%,仅指南推荐的 albumin 与院内死亡率降低相关(HR 0.73,95%CI 0.59-0.91),SBP集束化指标完成数越多,12个月出院后死亡风险越低。

要点

  • 新诊断SBP患者院内死亡率为15.5%,12个月死亡率为56.6%。
  • 指南推荐的 albumin 是唯一与院内死亡率降低相关的单项指标(HR 0.73,95%CI 0.59-0.91)。
  • 完成3、4、5项SBP集束化指标者较≤2项者12个月出院后死亡风险分别低20%、38%、56%(均p<0.001)。

核心结论

  • 前瞻性实施循证SBP集束化措施可能改善SBP的诊疗结局与死亡率。

研究设计与样本

  • 全国性队列研究,纳入4330例经腹水标准确诊的新诊断SBP患者。
  • 研究评估单项及集束化质量指标与结局的关联,并对卫生系统、患者临床因素及质量指标进行多水平校正。

主要发现

  • 院内死亡率为15.5%,12个月死亡率为56.6%。
  • 1期AKI发生率为26.6%,2期为15.7%,3期为22.8%。
  • SBP复发的累积发生率为10.3%。
  • 指南推荐的 albumin 是唯一与院内死亡率降低相关的单项指标(HR 0.73,95%CI 0.59-0.91)。
  • 完成3、4、5项SBP集束化指标者较接受≤2项者12个月出院后死亡风险分别低20%、38%、56%(均p<0.001);SBP集束化措施与3期AKI(对比0-2期)发生率降低相关(OR 0.66,95%CI 0.51-0.86)。

关键数值与推荐

  • 单项及集束化质量指标包括:48小时内住院抗生素、静脉 albumin、48小时内重复腹腔穿刺、SBP识别、出院时预防性抗生素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Spontaneous bacterial peritonitis (SBP) leads to high rates of acute kidney injury (AKI), hepatorenal syndrome, and mortality. Population-based studies on contemporary SBP epidemiology are needed to inform care. In a large, national cohort of patients diagnosed with SBP and confirmed by ascitic fluid criteria, we characterized ascitic fluid characteristics, in-hospital and 12-month mortality, AKI, and recurrent SBP. APPROACH AND RESULTS: We investigated how individual and bundled quality measures for SBP associated with outcomes after multi-level adjustment for health-system, patient clinical factors, and quality measures. Individual and bundled quality metrics were inpatient antibiotics within 48 hours, i.v. albumin, repeat paracentesis within 48 hours, recognition of SBP, and prophylactic antibiotics upon discharge. Among 4330 patients with newly diagnosed SBP, in-hospital mortality was 15.5%, and 12-month mortality was 56.6%. The incidence of stage 1 AKI was 26.6%, 15.7% for stage 2, and 22.8% for stage 3. The cumulative incidence of recurrent SBP was 10.3%. Guideline-recommended albumin was the only individual metric associated with reduced in-hospital mortality (HR: 0.73, 95% CI: 0.59-0.91). Receipt of a higher number of metrics from the SBP bundle was associated with progressively lower 12-month post-discharge mortality: patients who received 3, 4, and 5 SBP bundle components had 20%, 38%, and 56% lower hazard of mortality, respectively, relative to those receiving 2 or fewer (all p <0.001). The SBP bundle was associated with a lower incidence of stage 3 versus stage 0-2 AKI (OR: 0.66, 95% CI: 0.51-0.86). CONCLUSIONS: Prospective implementation of evidence-based SBP bundles may improve care outcomes and mortality in SBP.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Serper M, Tang H, Zhang S, et al. Clinical outcomes and care for spontaneous bacterial peritonitis: A national cohort study. Hepatology. 2025. PMID: 39879583. doi:10.1097/HEP.0000000000001251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。